flow study semaglutide reduces cardiovascular events in type 2 diabetes: a systematic review and meta-analysis highlighting enhanced benefits in chronic kidney disease | European Journal of Medical Research FLOW trial Ozempic® (semaglutide injection)
Description
Stronger ones may be used on the hands, feet, or areas with thickened skin
It will be more expensive due to higher manufacturing cost and patent exclusivity
Initially developed for type 2 diabetes, these agents are now widely used to achieve significant weight loss in individuals with obesity or overweight with comorbidities
Understanding its importance is vital for diagnosis and treatment
